Updating results

16 results

Sort: Relevance | Date

Supporting adult carers (NG150)

This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

NICE guideline Published January 2020

Episcissors-60 for mediolateral episiotomy (MTG47)

Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy

Medical technologies guidance Published February 2020

gammaCore for cluster headache (MTG46)

Evidence-based recommendations on gammaCore for cluster headache

Medical technologies guidance Published December 2019

Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)

Evidence-based recommendations on Virtual Touch Quantification for diagnosing and monitoring liver fibrosis in chronic Hepatitis B and C

Medical technologies guidance Published September 2015 Last updated January 2020

Cladribine for treating relapsing–remitting multiple sclerosis (TA616)

Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults

Technology appraisal guidance Published December 2019

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older

Technology appraisal guidance Published December 2019

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older

Technology appraisal guidance Published December 2019

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a

Technology appraisal guidance Published August 2019 Last updated February 2020

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

Technology appraisal guidance Published February 2020

Patiromer for treating hyperkalaemia (TA623)

Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults

Technology appraisal guidance Published February 2020

Sotagliflozin with insulin for treating type 1 diabetes (TA622)

Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

Technology appraisal guidance Published February 2020

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published January 2020

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

Evidence-based recommendations on olaparib (Lynparza) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a

Technology appraisal guidance Published January 2020

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Technology appraisal guidance Published January 2020

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC

Technology appraisal guidance Published January 2020

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

Technology appraisal guidance Published January 2020